New hope for tough prostate cancer: early trial of ACE-232 begins
Disease control
Recruiting now
This early-phase study tests a new drug called ACE-232 in about 67 men with a hard-to-treat type of advanced prostate cancer (metastatic castration-resistant prostate cancer). The main goals are to check the drug's safety, find the best dose, and see early signs it might help con…
Phase: PHASE1 • Sponsor: Acerand Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated May 14, 2026 12:04 UTC